title: Recommendations for 'adequate evaluation of hormone receptors' a report of the task force of the Japanese Breast Cancer Society.
abstract: The task force of the Japanese Breast Cancer Society was assembled to examine variable factors related to the immunohistochemical evaluation of hormone receptors in breast cancer, and to provide recommendations for adequate handling of specimens and accurate evaluations for hormone receptors. The various factors examined were: i) the adequate handling of breast cancer tissue for IHC, ii) the concordant rate between EIA and IHC assays using 5 different staining methods, iii) the inter-observer diversity for evaluation, and iv) the threshold for the predictive value of endocrine therapy of primary and recurrent/metastatic breast cancers. The conducted studies found that a 10% threshold was stable and reliable in spite of different validations including the concordance between IHC and EIA assays, inter-observer diversity and disease-free survival rates for patients who received tamoxifen for primary breast cancers. It was also found that 1% of threshold was useful in limited situations including the predictive value of endocrine therapy for recurrent/metastatic breast cancers. Based on these results for technical, pathological and clinical validation studies, a recommendation was proposed. Herein, we summarize the evidence, on which the recommendations were made, and customize the recommendations suitable for the current status.
authors.affiliation: Department of Pathology, Tokai University School of Medicine, Isehara 259-1193, Japan. umemura@is.icc.u-tokai.ac.jp
authors.forename: Shinobu
authors.initials: S
authors.lastname: Umemura
authors.forename: Masafumi
authors.initials: M
authors.lastname: Kurosumi
authors.forename: Takuya
authors.initials: T
authors.lastname: Moriya
authors.forename: Tetsunari
authors.initials: T
authors.lastname: Oyama
authors.forename: Kohji
authors.initials: K
authors.lastname: Arihiro
authors.forename: Hiroko
authors.initials: H
authors.lastname: Yamashita
authors.forename: Yoshihisa
authors.initials: Y
authors.lastname: Umekita
authors.forename: Yoshifumi
authors.initials: Y
authors.lastname: Komoike
authors.forename: Chikako
authors.initials: C
authors.lastname: Shimizu
authors.forename: Hisaki
authors.initials: H
authors.lastname: Fukushima
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Kajiwara
authors.forename: Futoshi
authors.initials: F
authors.lastname: Akiyama
mesh_terms: D026683:Advisory Committees / Q000458:organization & administration; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D019411:Clinical Laboratory Techniques / Q000379:methods / Q000592:standards*; D003940:Diagnostic Techniques, Endocrine / Q000639:trends; D005260:Female; D006287:Health Planning Guidelines; D006801:Humans; D007564:Japan; D008495:Medical Oncology / Q000379:methods / Q000592:standards*; D018160:Receptors, Cytoplasmic and Nuclear / Q000032:analysis* / Q000235:genetics / Q000378:metabolism; D012106:Research / Q000639:trends
chemical_list: D018160:Receptors, Cytoplasmic and Nuclear